Market Overview:
The global liposomal and lipid nanoparticle drug delivery systems market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for targeted drug delivery systems, and technological advancements in the field of liposomal and lipid nanoparticle drug delivery systems. Based on type, the global liposomal and lipid nanoparticle drug delivery systems market is segmented into liposomes drugs and lipid nanoparticle drugs. Liposomes drugs are further sub-segmented into small unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs). Lipid nanoparticles are further sub-segmented into solid lipid particles (SLPs) and liquid crystal dispersions (LCDs). Based on application, the global liposomal and lipid nanoparticle drug delivery systems market is segmented into hospital, retail pharmacy, other. Geographically, the global liposomal and lipid nanoparticle drug delivery systems market is segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
Liposomes and lipid nanoparticles are drug delivery systems that are made of lipids, which are natural fats. These systems can be used to deliver drugs to specific parts of the body. This is important because it can allow for more accurate treatment of diseases. Additionally, these systems can help reduce the side effects of drugs by delivering them directly to the cells that need them.
Liposomes Drugs:
Liposomes are small vesicular structures composed of phospholipids and water. They are naturally occurring organelles that play a major role in the transport of hydrophobic drugs across membranes. Liposomes are non-immunogenic particles made up of individual lipid molecules held together by intermolecular forces, which allow them to cross membranes easily.
Lipid Nanoparticle Drugs:
Lipid nanoparticle drugs and its usage in Liposomal and Lipid Nanoparticle Drug Delivery Systems market is a new emerging trend in the pharmaceutical industry. The main objective of using lipid nanoparticles (LNPs) as drug carriers is to enhance the bioavailability of drugs by improving their absorption, distribution, metabolism & excretion properties. LNPs are also used for targeted delivery of drugs to ensure maximum efficacy in tumor cells with minimum exposure of drug to other tissues.
Application Insights:
The other application segment includes research applications. Other applications of liposomal and lipid nanoparticle drug delivery systems include cancer treatment, gene therapy, and viral disease management. The other application segment held the largest share in 2017 owing to increasing R&D activities for developing novel uses of these nanotechnology-based formulations for treating various diseases such as HIV/AIDS, Hepatitis C & B viruses, multiple sclerosis symptoms etc.
Hospital was the largest revenue generating segment in 2017 owing to wide usage of these formulations for delivering drugs at desired sites within the body (targeted delivery). Targeted drug Delivery Systems (DDDS) are used by hospitals to deliver a particular type of medication that is effective for specific conditions requiring individualized treatment at a precise site within the body. Liposomes are preferred over small molecules due to their ability to recognize cells and interact with them; this property makes them an ideal carrier vehicle for targeted drug delivery systems used in hospital settings across North America and Europe regions.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of pharmaceutical and biopharmaceutical companies involved in drug discovery and development. Moreover, increasing R&D activities by these companies for nanoparticle-based drug delivery systems is one of the major factors responsible for this dominance. The U.S.-based company Nanovi A/S has developed a novel method to manufacture liposomes that are used as vehicles for delivering drugs (lipid nanoparticles) into cells or tumors [1].
Asia Pacific is expected to grow at an exponential rate during the forecast period due to rising healthcare expenditure, growing target population base, improving economic conditions leading to increased disposable income levels, and rapid technological advancements resulting in enhanced product penetration across various verticals including medical sector. Japan leads this regional market followed by China on account of government support aimed at promoting innovation through tax benefits etc., which encourages research & development activities within these countries [2].
Growth Factors:
- Increasing demand for targeted drug delivery systems: The growing demand for targeted drug delivery systems is one of the key growth drivers for the liposomal and lipid nanoparticle drug delivery systems market. This is because these systems can improve the efficacy and safety of drugs by delivering them to specific cells or tissues.
- Rising prevalence of chronic diseases: The rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular disorders, is another major factor that is expected to drive the growth of this market in the coming years.
- Growing investment in R&D activities: There has been a significant increase in investment in R&D activities for liposomal and lipid nanoparticle drug delivery systems over the past few years, owing to their potential applications in various therapeutic areas. This is likely to boost the growth of this market in future.
- Technological advancements: The development of novel technologies for manufacturing liposomal and lipid nanoparticle drug delivery systems has led to an increase in their adoption across various application areas. This is likely to propel the growth of this market during forecast period 2017-2025 . 5) Emerging markets offer lucrative opportunities: The emerging markets are expected to offer lucrative opportunities for players operating in this market due to their high population base and increasing spending on healthcare infrastructure
Scope Of The Report
Report Attributes
Report Details
Report Title
Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Research Report
By Type
Liposomes Drugs, Lipid Nanoparticle Drugs
By Application
Hospital, Retail Pharmacy, Other
By Companies
Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen, Sayre Therapeutics, Jazz, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, Gilead Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Report Segments:
The global Liposomal and Lipid Nanoparticle Drug Delivery Systems market is segmented on the basis of:
Types
Liposomes Drugs, Lipid Nanoparticle Drugs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Retail Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Johnson & Johnson
- Sun Pharmaceutical
- CSPC
- Kinyond
- Teva
- Fudan-Zhangjiang
- Zydus Cadila
- TTY Biopharma
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Ipsen
- Sayre Therapeutics
- Jazz
- Alnylam
- Bausch Health
- Acrotech Biopharma
- Takeda
- Chiesi Farmaceutici
- Gilead Sciences
Highlights of The Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Liposomes Drugs
- Lipid Nanoparticle Drugs
- By Application:
- Hospital
- Retail Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Liposomal and Lipid Nanoparticle Drug Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Liposomal and lipid nanoparticle drug delivery systems are nanotechnology-based systems that can safely and effectively transport drugs to specific locations in the body. Liposomes are small, water-containing spheres made of phospholipids (a type of lipid). Lipid nanoparticles are tiny balls or particles made up of lipids. They can be designed to carry a variety of drugs and other therapeutic agents.
Some of the major players in the liposomal and lipid nanoparticle drug delivery systems market are Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen, Sayre Therapeutics, Jazz, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, Gilead Sciences.
The liposomal and lipid nanoparticle drug delivery systems market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Liposomal and Lipid Nanoparticle Drug Delivery Systems Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size & Forecast, 2018-2028
4.5.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size and Y-o-Y Growth
4.5.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Absolute $ Opportunity
Chapter 5 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Type
5.2.1 Liposomes Drugs
5.2.2 Lipid Nanoparticle Drugs
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Retail Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Analysis and Forecast
9.1 Introduction
9.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Type
9.6.1 Liposomes Drugs
9.6.2 Lipid Nanoparticle Drugs
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Retail Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Analysis and Forecast
10.1 Introduction
10.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Type
10.6.1 Liposomes Drugs
10.6.2 Lipid Nanoparticle Drugs
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Retail Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Type
11.6.1 Liposomes Drugs
11.6.2 Lipid Nanoparticle Drugs
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Retail Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Analysis and Forecast
12.1 Introduction
12.2 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Type
12.6.1 Liposomes Drugs
12.6.2 Lipid Nanoparticle Drugs
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Retail Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Liposomal and Lipid Nanoparticle Drug Delivery Systems Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Type
13.6.1 Liposomes Drugs
13.6.2 Lipid Nanoparticle Drugs
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Retail Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market: Competitive Dashboard
14.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Johnson & Johnson
14.3.2 Sun Pharmaceutical
14.3.3 CSPC
14.3.4 Kinyond
14.3.5 Teva
14.3.6 Fudan-Zhangjiang
14.3.7 Zydus Cadila
14.3.8 TTY Biopharma
14.3.9 Pacira
14.3.10 Luye Pharma
14.3.11 Leadiant Biosciences
14.3.12 Ipsen
14.3.13 Sayre Therapeutics
14.3.14 Jazz
14.3.15 Alnylam
14.3.16 Bausch Health
14.3.17 Acrotech Biopharma
14.3.18 Takeda
14.3.19 Chiesi Farmaceutici
14.3.20 Gilead Sciences
